Nanomab is advised by an expert scientific advisory board.

Prof. H.J. Biersack
Prof. Biersack is a distinguished nuclear medicine physician who previously served as senator and vice rector of the University of Bonn, Germany, the president of World Federation of nuclear medicine and biology, chairman of the German Society of nuclear medicine, congress president of the Deutsche Gesellschaft für Nuklearmedizin (DGN, German Society for Nuclear Medicine). He is a well-known expert in nuclear medicine and imaging field publishing 650 research paper, 650 abstracts, 310 book chapters and 35 books. He won numerous honors during his career. The honors may include but not limited to: Order of Merit (Federal Republic of Germany), Sign of Honor (International Red Cross), Werner Heisenberg Medaille, etc.
Dr. YK Wan
Dr. Wan is the CEO of Shanghai Novamab biopharmaceutical company. He is an leading expert in the development of Camelid sdAb with more than 40 screening projects up to date at different stage of clinical and preclinical development. He also served as principal investigator at Shanghai Institute of Materia Medica (CAS) and Southeast University before starting Novamab in 2018. He received his PhD degree in the Institute of Botany, the Chinese Academy of Science, and his postdoctoral training in the University of Texas at Austin, the Baylor College and the Institute for Systems Biology in US.
Prof. Cook is Professor of Clinical PET Imaging at King’s College London and honorary consultant physician at Guy’s and St Thomas’ NHS Foundation Trust.
Prof. Cook’s group in the Cancer Imaging Department in the School of Biomedical Engineering and Imaging Sciences at KCL, mainly focuses on multimodality imaging of skeletal metastases; evaluation of novel tracers for oncological SPECT and PET imaging; multimodality multiparametric imaging biomarker development and measurement of tumour heterogeneity.
He has over 200 publications and has received several awards.
Dr. Austin Smith
Austin received his medical degree from the Royal College of Physicians in Ireland in 1993. He spent the following 14 years working within the healthcare system with extensive time training and working at the internationally renowned Hammersmith Hospital and The Royal Marsden Trust, rising to a position as Resident Oncologist at The London Clinic, one of the UK’s largest private hospitals. From there he transitioned into the CRO industry, and for the past decade he has held a position as Medical Director, Early and Experimental Oncology Clinical Development at Theradex Oncology. Austin has also undertaken specialist accreditation training as a Pharmaceutical Physician.